Wasedoc contains dabigatran etexilate as the active substance and belongs to a group of medicines called anticoagulants. Its action involves blocking a substance in the body responsible for the formation of blood clots.
Wasedoc is used in adults to:
Wasedoc is used in children to:
PT/H/2645/001-003/IB/006
ryzyko dużego krwawienia (np. choroba wrzodowa żołądka, uraz mózgu lub krwawienie
do mózgu, niedawno przebyta operacja mózgu lub oczu).
Before starting treatment with Wasedoc, you should discuss it with your doctor. If you have experienced symptoms or undergone surgery during treatment with this medicine, you should consult your doctor.
The patient should inform the doctorif they have or have had any medical conditions or diseases, especially those listed below:
PT/H/2645/001-003/IB/006
You should tell your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
In particular, before taking Wasedoc, you should tell your doctor if you are taking any of the following medicines:
PT/H/2645/001-003/IB/006
The effect of Wasedoc on pregnancy and the unborn child is not known. You should not take this medicine during pregnancy, unless your doctor considers it safe.
Women of childbearing age should avoid becoming pregnant while taking Wasedoc.
You should not breastfeed while taking Wasedoc.
Wasedoc has no or negligible influence on the ability to drive and use machines.
This medicine contains less than 1 mmol (23 mg) of sodium per capsule, which means that it is essentially "sodium-free".
Wasedoc capsules can be used in adults and children aged 8 years or older who can swallow the capsules whole. There are other age-appropriate pharmaceutical forms for the treatment of children under 8 years of age.
This medicine should always be taken exactly as prescribed by your doctor. If you are unsure, you should consult your doctor.
Prevention of blood clots in the brain and body, by preventing the formation of clots that occur during abnormal heart function, and treatment of blood clots in the veins of the legs and lungs, and prevention of recurrence of blood clots in the veins of the legs and lungs.
The recommended dose is 300 mg taken as one 150 mg capsule twice a day.
For patients aged 80 years or older, the recommended dose of Wasedoc is 220 mg taken as one 110 mg capsule twice a day.
Patient taking medicines containing verapamilshould receive a reduced dose of Wasedoc, 220 mg taken as one 110 mg capsule twice a day, due to the possible increased risk of bleeding.
For patients with potentially increased risk of bleeding, the doctor may recommend a dose of 220 mg taken as one 110 mg capsule twice a day.
Treatment can be continued if the patient needs to restore normal heart function using a procedure called cardioversion or using a procedure called catheter ablation in atrial fibrillation. Wasedoc should be taken as prescribed by your doctor.
PT/H/2645/001-003/IB/006
In the case of implantation of a medical device (stent) into a blood vessel to maintain its patency using a procedure called percutaneous coronary intervention with stent implantation, the patient may be treated with Wasedoc, after the doctor has confirmed that adequate blood clotting control has been achieved. Wasedoc should be taken as prescribed by your doctor.
Treatment of blood clots and prevention of recurrence of blood clots in children
Wasedoc should be taken twice a day, one dose in the morning and one dose in the evening, at approximately the same time every day. The interval between doses should be approximately 12 hours.
The recommended dose depends on body weight and age. The doctor will determine the correct dose. The doctor may adjust the dose during treatment. You should continue to take all other medicines, unless your doctor advises you to stop taking any of them.
Table 1 shows the single and total daily doses of Wasedoc in milligrams (mg). The doses depend on the patient's body weight in kilograms (kg) and age in years.
Body weight and age ranges | Single dose in mg | Total daily dose in mg | |
Body weight in kg | Age in years | ||
from 11 to less than 13 kg | from 8 to less than 9 years | 75 | 150 |
from 13 to less than 16 kg | from 8 to less than 11 years | 110 | 220 |
from 16 to less than 21 kg | from 8 to less than 14 years | 110 | 220 |
from 21 to less than 26 kg | from 8 to less than 16 years | 150 | 300 |
from 26 to less than 31 kg | from 8 to less than 18 years | 150 | 300 |
from 31 to less than 41 kg | from 8 to less than 18 years | 185 | 370 |
from 41 to less than 51 kg | from 8 to less than 18 years | 220 | 440 |
from 51 to less than 61 kg | from 8 to less than 18 years | 260 | 520 |
from 61 to less than 71 kg | from 8 to less than 18 years | 300 | 600 |
from 71 to less than 81 kg | from 8 to less than 18 years | 300 | 600 |
81 kg or more | from 10 to less than 18 years | 300 | 600 |
Doses requiring the combination of more than one capsule:
300 mg:
two 150 mg capsules or four 75 mg capsules
260 mg:
one 110 mg capsule and one 150 mg capsule or
one 110 mg capsule and two 75 mg capsules
220 mg:
two 110 mg capsules
185 mg:
one 75 mg capsule and one 110 mg capsule
150 mg:
one 150 mg capsule or two 75 mg capsules
PT/H/2645/001-003/IB/006
Wasedoc can be taken with or without food. The capsules should be swallowed whole, with a glass of water, to facilitate passage into the stomach. They should not be broken, chewed or the pellets spilled from the capsule, as this may increase the risk of bleeding.
Do not change your anticoagulant medicine without receiving detailed instructions from your doctor.
Taking too much of this medicine increases the risk of bleeding. If you have taken too many Wasedoc capsules, you should immediately contact your doctor. There are specific treatments available.
A missed dose can be taken up to 6 hours before the next scheduled dose.
If there are less than 6 hours until the next scheduled dose, you should not take the missed dose. You should not take a double dose to make up for a missed dose.
Wasedoc should be taken as prescribed by your doctor. You should not stop taking this medicine without consulting your doctor first, as the risk of blood clot formation may be higher if treatment is stopped prematurely. You should contact your doctor if you experience nausea after taking Wasedoc.
If you have any further questions about the use of this medicine, you should ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Wasedoc affects the blood clotting system, so most side effects are related to symptoms such as bruising or bleeding. Major or severe bleeding may occur, which is the most serious side effect and can lead to disability, be life-threatening, or even fatal, regardless of the location. In some cases, these bleeding events may not be visible.
If you experience bleeding that does not stop on its own, or symptoms of excessive bleeding (exceptional weakness, fatigue, pallor, dizziness, headache or unexplained swelling), you should immediately contact your doctor. The doctor may decide to closely monitor you or change the medicine.
If you experience a severe allergic reaction that can cause breathing difficulties or dizziness, you should immediately contact your doctor.
The following side effects are grouped by frequency:
Prevention of blood clots in the brain and body, by preventing the formation of clots that occur during abnormal heart function
PT/H/2645/001-003/IB/006
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Unknown frequency (cannot be estimated from the available data):
In clinical trials, the number of heart attacks in patients taking Wasedoc was higher than in patients taking warfarin. The overall number of events was low.
Treatment of blood clots in the veins of the legs and lungs, and prevention of recurrence of blood clots in the veins of the legs and lungs
PT/H/2645/001-003/IB/006
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people):
Unknown frequency (cannot be estimated from the available data):
In clinical trials, the number of heart attacks in patients taking Wasedoc was higher than in patients taking warfarin. The overall number of events was low. No difference in the number of heart attacks was observed in patients treated with dabigatran compared to patients who received placebo.
Treatment of blood clots and prevention of recurrence of blood clots in children
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Unknown frequency (cannot be estimated from the available data):
If you experience any side effects, including any not listed in this leaflet, you should tell your doctor or pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products:
Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: 22 49-21-301, fax: 22 49-21-309,
website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and blister after:
"EXP". The expiry date refers to the last day of the month stated.
Blister: The medicine does not require special storage conditions. The capsules should not be placed in pill boxes or pill organizers unless they can be stored in their original packaging.
Medicines should not be disposed of via wastewater. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Wasedoc is a hard capsule.
Wasedoc, 150 mg is a non-transparent, pink hard capsule with the imprint "DA150".
Wasedoc, 150 mg is available in packs containing 30 or 60 hard capsules, or in multipacks containing 3 packs of 60 hard capsules (180 hard capsules) in aluminum perforated blisters Aluminum/OPA/Aluminum/PE with a desiccant, in a cardboard box.
Not all pack sizes may be marketed.
Ranbaxy (Poland) Sp. z o.o.
ul. Idzikowskiego 16
00-710 Warsaw
Pharmadox Healthcare Ltd.
KW20A Kordin Industrial Park
Paola, PLA 3000
Malta
TOWA PHARMACEUTICAL EUROPE, S.L.
C/ de Sant Martí, 75-97
08107 Martorelles (Barcelona)
Spain
Terapia S.A.
Str. Fabricii nr. 124
400632, Cluj-Napoca
Romania
Romania: Wasedoc
Portugal: Wasedoc
Date of last revision of the leaflet: 04.08.2023
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.